Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed No phase listed Observational Accepts healthy volunteers

CSD201004: An Actual Use Study of P10 and P13 Nicotine Pouches Among U.S. Adult Smokers

ClinicalTrials.gov ID: NCT05184920

Public ClinicalTrials.gov record NCT05184920. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 7, 2026, 6:44 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this Actual Use Study (AUS) is to investigate how U.S. adult tobacco consumers 21-60 years of age) who are regular smokers (≥5 cigarettes/day) on at least 20 days out of the past 30 days will use P10 and P13 nicotine pouches (Study Investigational Product \[IP\]) over a 6-week Actual Use Period (AUP) in their real-life/naturalistic environment and in the context of typical consumer marketing materials. Subjects will self-report their ad libitum use of the Study IP as well as use of combustible cigarette (CC) and any other tobacco- or nicotine-containing product (TNP) on a daily basis using an electronic diary (eDiary). The study design is planned to address topics that FDA's Center for Tobacco Products (CTP) has identified as useful in evaluating new tobacco products.

Study identification

NCT ID
NCT05184920
Recruitment status
Completed
Study type
Observational
Phase
Not listed
Lead sponsor
RAI Services Company
Industry
Enrollment
1,105 participants

Conditions and interventions

Eligibility (public fields only)

Age range
21 Years to 60 Years
Sex
All
Healthy volunteers
Accepts healthy volunteers

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jan 18, 2022
Primary completion
Apr 28, 2022
Completion
Apr 28, 2022
Last update posted
Jun 26, 2022

2022

United States locations

U.S. sites
10
U.S. states
8
U.S. cities
10
Facility City State ZIP Site status
Schlesinger Phoenix Phoenix Arizona 85016
Schlesinger Atlanta Atlanta Georgia 30328
Schlesinger Chicago Chicago Illinois 60611
Schlesinger Kansas City Kansas City Missouri 64114
Schlesinger St. Louis St Louis Missouri 63131
Schlesinger New Jersey Iselin New Jersey 08830
Schlesinger Columbus Columbus Ohio 43235
Schlesinger Philadelphia Philadelphia Pennsylvania 19103
Schlesinger Dallas Dallas Texas 75254
Schlesinger Houston Houston Texas 77027

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT05184920, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jun 26, 2022 · Synced Sep 7, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT05184920 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →